PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10381483" target="_blank" >RIV/00216208:11110/18:10381483 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/18:10381483 RIV/00669806:_____/18:10381483 RIV/00064165:_____/18:10381483
Result on the web
<a href="http://iv.iiarjournals.org/content/32/6/1551.long" target="_blank" >http://iv.iiarjournals.org/content/32/6/1551.long</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/invivo.11413" target="_blank" >10.21873/invivo.11413</a>
Alternative languages
Result language
angličtina
Original language name
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study
Original language description
Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. Materials and Methods: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). Results: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
In Vivo
ISSN
0258-851X
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
6
Country of publishing house
GR - GREECE
Number of pages
4
Pages from-to
1551-1554
UT code for WoS article
000447885500035
EID of the result in the Scopus database
2-s2.0-85055180893